Charles Schwab
MBRX icon

Charles Schwab’s Moleculin Biotech MBRX Stock Holding History

Charles Schwab’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-98
Closed -$38.8K – 3575
2022
Q4 		$38.8K Buy
+98
New +$41.4K ﹤0.01% 3410
2022
Q3 		– Sell
-84
Closed -$46K – 3534
2022
Q2 		$46K Buy
84
+30
+56% +$17.5K ﹤0.01% 3403
2022
Q1 		$36K Hold
54
– – ﹤0.01% 3564
2021
Q4 		$38K Hold
54
– – ﹤0.01% 3533
2021
Q3 		$61K Buy
+54
New +$63K ﹤0.01% 3427
2021
Q2 		– Sell
-32
Closed -$50K – 3489
2021
Q1 		$50K Buy
+32
New +$58.6K ﹤0.01% 3436

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Charles Schwab's MBRX Position: Q1 2023 in Review

Charles Schwab sold out of Moleculin Biotech (MBRX) in Q1 2023, closing a stake of 98 shares — an estimated $38.8K sold.

Charles Schwab first reported a position in MBRX in Q1 2021 and held it in 6 quarters. The position peaked at $61K in Q3 2021. 22 funds tracked by Wall St. Rank hold MBRX as of Q1 2023.

  • Charles Schwab reported no remaining Moleculin Biotech position as of Q1 2023 after selling out during the quarter.
  • Charles Schwab sold 98 Moleculin Biotech shares in Q1 2023, an estimated $38.8K.
  • Charles Schwab first reported a position in Moleculin Biotech in Q1 2021 and held it in 6 quarters.
  • Charles Schwab's Moleculin Biotech position peaked at $61K in Q3 2021.
  • 22 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2023.

Based on Charles Schwab's 13F filing for Q1 2023, filed 12 May 2023.